Results 261 to 270 of about 172,205 (306)

Identification of a novel <i>PRUNE2::NTRK2</i> gene fusion in soft tissue sarcoma patients-friend or foe? Case series. [PDF]

Ther Adv Med Oncol
Bobak K, Tysarowski A, Seliga KA, Pia̧tkowski J, Golik P, Spałek MJ, Szumera-Ciećkiewicz A, Rutkowski P, Czarnecka AM.   +8 more
europepmc   +1 more source

Mitochondrial reprogramming in lung cancer: a therapeutic vulnerability and a strategy for reversing drug resistance

The Journal of Pathology, Volume 269, Issue 2, Page 149-163, June 2026.
Abstract The conceptualization of mitochondria, previously restricted to their function as cellular ‘powerhouses’, has evolved to recognize their function as central coordinating hubs for the orchestration of cancer cell metabolism, signaling, and fate determination.
Woo Hyun Park
wiley   +1 more source

Identification of a <i>Musashi2</i> translocation as a novel oncogene in myeloid leukemia. [PDF]

Elife
Spinler K, Hamilton M, Bajaj J, Shima Y, Diaz E, Kritzik M, Reya T.   +6 more
europepmc   +1 more source

Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations

The Journal of Pathology, Volume 269, Issue 2, Page 164-181, June 2026.
Abstract Lung cancer is the leading cause of global cancer‐related morbidity and mortality, with tobacco smoking as its strongest risk factor. Nuclear factor erythroid 2‐related factor 2 (NRF2) is a redox‐regulated transcription factor frequently dysregulated in non‐small cell lung cancer (NSCLC), leading to aggressive disease and resistance to therapy.
Jouni Härkönen, Satu Tiainen, Jouni Kujala, Linnea Muhonen, Ponnuswamy Mohanasundaram, Tuomas Tikkanen, Ina Pöhner, Tommi Patinen, Simone Adinolfi, Juha P Väyrynen, Päivi Auvinen, Arto Mannermaa, Petri Pölönen, Tuomas Rauramaa, Anna‐Liisa Levonen   +14 more
wiley   +1 more source

Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR. [PDF]

Transl Oncol
Li H, Wei H, Zhen T, Gao H, Liu H, Zheng S, Shi H, Liang J, Zhang F, Ye J, Lin G, Han A.   +11 more
europepmc   +1 more source

Pitfalls and missing links in current understanding of 4D genomes

Quantitative Biology, Volume 14, Issue 2, June 2026.
Abstract The spatial and temporal organization of the genome—collectively termed the 4D genome—is pivotal for regulating gene expression, maintaining genome stability, and guiding development. The convergence of chromosome conformation capture technologies, super‐resolution microscopy, and single‐cell epigenomics has transformed our understanding of ...
Michael Q. Zhang
wiley   +1 more source

A new KAT on the block rewrites the epigenetic script in menin inhibitor-resistant leukemia. [PDF]

Hemasphere
Huang Y, de Bock CE.
europepmc   +1 more source

PAX8‐positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles – A clinicopathologic study of 101 consecutive cases with next‐generation sequencing in 20 cases

Histopathology, Volume 88, Issue 7, Page 1315-1323, June 2026.
PAX8 expression in urothelial carcinoma was investigated in 101 consecutive transurethral resections of the urinary bladder. PAX8 was positive in 10% of cases, with targeted molecular testing of these cases revealing universal TERT promoter mutations and frequent alterations in TSC1, NOTCH1 and WT1. Aims PAX8 immunohistochemistry (IHC) is often used to
Sarah Mae Lammert, Wendy Luo, Allen C Zhu, Peng Wang, Tatjana Antic, Jung Woo Kwon   +5 more
wiley   +1 more source

FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies. [PDF]

Cancers (Basel)
Xin X, Miao R.
europepmc   +1 more source

<i>ROS1</i>-positive non-small cell lung cancer: from genomics to treatment decisions. [PDF]

Front Oncol
Wespiser M, Gille R, Pérol M.
europepmc   +1 more source